Current Report Filing (8-k)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) August 11, 2022

INNOVATION1 BIOTECH INC.

(Exact name of registrant as specified in its charter)

Nevada

000-55852

82-2275255

(State or other jurisdiction of

incorporation or organization)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

40 Wall Street, Suite 2701

New York, New York 10005

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (646) 380-1923

_____________________________________________

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

none

not applicable

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of Dr. Andrew Salzman as a Director

On August 11, 2022, the Board of Directors of Inovation1 Biotech, Inc. has appointed Andrew L. Salzman, MD as a member of the Board. Dr. Salzman also serves as the Company’s Chief Science Officer. A copy of the press release is included as Exhibit 99.1 to this Current Report.

Dr. Salzman, age 66, was appointed as our Chief Science Officer in January 2022. He also serves as Chairman and Chief Scientist of Salzman Group, Inc. Salzman Group, Ltd. (UK), Beetlebung Pharmaceuticals, Ltd., Salzman Investments, Ltd., Quitsa Pharmaceuticals, Ltd., Salzman Group Ltd. (Israel), Salzman Group Pty Ltd. and Herring Creek Pharmaceuticals, Inc since August 2017 and Elati GmbH since January 2022. Dr. Salzman also served as Chairman and Chief Scientist of AOX Pharma from August 2018 to June 2019. Since November 2021, Dr. Salzman has been a Consulting Chief Scientist at ViroBlock Ltd. and Wonderfeel, Inc. From August 2021 to November 2021, Dr. Salzman served as Chief Medical officer of ST Biosciences, Ltd. Additionally, he was a Consulting Scientist to Claritas Pharmaceuticals, Inc. from August 2017 to June 2022. Dr. Salzman earned his Doctor of Medicine degree from Harvard Medical School after completing undergraduate training at Yale College. Dr. Salzman completed his pediatric internship and residency at Columbia University, and post-doctoral fellowships in pediatric critical care, neonatal critical care, immunology, mucosal physiology, and pediatric infectious disease at the Weizmann Institute of Science, Boston Children’s Hospital Medical Center, the Massachusetts General Hospital, and Beth Israel Hospital Medical Center.

Item 7.01. Regulation FD Disclosure.

On August 12, 2022, Innovation1 Biotech Inc. (the “Company”) posted an updated presentation (the “Presentation”) which is available in the Presentations section of the Company’s website at https://www.innovation1bio.com/company-information/presentations. A copy of the Presentation is included as Exhibit 99.2 to this Current Report.

The Company intends to use the Presentation in presentations to investors and analysts from time to time in the future. The furnishing of the information in this Current Report is not intended to, and does not, constitute a determination by the Company that the information in this Current Report is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company. The information in the materials is presented as of August 12, 2022, and the Company does not assume any obligation to update such information in the future.

The information in Item 7.01 of this Current Report shall not be deemed to be "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1		Press Release dated August 11, 2022.

99.2		Innovation1 Biotech Inc. Presentation dated August 12, 2022.

104		Cover Page Interactive Data File (embedded within the Inline XBRL Document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.